DOCSLIB.ORG

( Anti-Obesity Agents ) Sibutramine Orlistat Rimonabant

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
( Anti-Obesity Agents ) Sibutramine Orlistat Rimonabant 2006 17 155-162 sibutramine orlistat rimonabant ( Anti-obesity agents ) Sibutramine Orlistat Rimonabant 5 12 15 1980 1986 1996 12.4% 14.8% 15.6% 10.1% 11.1% 12.9% ( metabolic syndrome ) 1993-1996 10.5% 2000-2001 15.9% 13.7% 10.7%1 2 2-4 704 138 156 BMI mulating hormone ( -MSH ) -MSH BMI menalocortin-4 ( MC4-R ) 27kg/m2 BMI <27 POMC 24kg/m2 6 MC4-R 11-13 Prader-Willi ( leptin resistance ) 14 Albright hereditary osteodystrophy Fragile X adiponectin resistin interleukin 6 ( IL-6 ) tumor necrosis fac- tor-alpha ( TNF- ) visfatin arcuate nu- cleus neuropep- tide Y ( NPY ) agouti-related peptide ( AgRP ) Ghrelin proopiomelanocortin ghrelin ( POMC ) cocaine-and amphetamine-regulated NPY AgRP transcript ( CART ) 15 ghrelin 16,17 18 7 ghrelin Cannabinoid system cholecystokinin glucagon-like peptide 1 ( GLP-1 ) pancreatic ( receptors ) polypeptide amylin peptide YY cannabinoid receptor 1 ( CB1 ) cannabinoid re- ceptor 2 ( CB2 ) CB1 CB2 cannabinoid system 8 CB1 9 CB1 blockage CB1 blockage ( ) ( ) 10 ( leptin ) ( leptin receptor ) POMC -melanocyte-sti- 157 Sibutramine 2 15 mg sibutramine 2 12 sibutra- mine 0.3 mmol/l 1.4 mmol/l ( p=0.04 ) Sibutramine ( Reductil® ® ) sibutramine 0.3% 0.0% Sibutramine ( p<0.05 ) 1.0% sibu- serotonin norepinephrine tramine 33% 5% ( SNRI ) ( p<0.05) 5% sibutramine 19% 0% ( fat mass ) sibutramine 7 1047 1.0% 0.0%( p<0.05 ) 24 24 1.8kg 0.2kg ( p<0.001 ) 24 1.2% Sibutramine sibutramine 1 mg 2.7% 5 mg 5 mg- 3.9% 10 mg 6.1% 15 mg 30 mg 7.4% 20 mg 8.8% 30 mg 10 mg 9.4% 4 15 mg 24 19 10 mg 5 mg 12 10 mg-15 mg 3-6 1.4±0.5kg sibutramine 5mg 4 mmHg 1% 2.4±0.5kg sibutramine 10 mg 25 5.1±0.5kg sibutramine 15 mg 4.9± 0.5kg 20 sibu- sibutramine tramine 21 Orlistat ( Xenical® ® ) 29 Orlistat sibutramine 10 20 mg/day sibutramine 3 l 2.78kg 4.45 kg 22 26 15 743 sibutramine 15 mg orli- stat 120 mg Orlistat 12.1±9.8kg 10.2% ( 10.3kg ) sibutramine 5.0±7.4kg 6.1% ( 6.2kg ) 6.7±7.9kg orlistat orlistat 76% 23 158 84% 6.6kg ( p<0.001 ) rimonabant 20mg orlistat 5% 10% 0.9kg HDL 2.5kg 27 triglyceride orlistat ( 12.9% ) ( 7.2% ) ( 8.7% ) orlistat 2.6% 10.4%28 orlistat 2 ( RIO- orlistat 6.2±0.45% North America )33 RIO-Europe 4.3±0.49% 5% rimonabant 20 mg orlistat 6.3kg 49% 23%29 1.6kg ( p<0.01 ) ( XENDOS ) HDL triglyceride BMI 30 rimonabant 20 mg orlistat 2 rimonabant 20 mg 9.0% orlistat 6.2% orlistat ( 11.2% ) 37.3% 3.0 kg orlistat 5.8kg ( p<0.001 ) 30 Orlistat (RIO-Lipid ) 34 rimonabant 79% orlistat 59% 5 mg 20 mg ( ) 4.2kg ( p<0.001 ) 8.6kg ( p<0.001 ) ( ) 31 rimonabant 20mg A D E beta- triglyceride leptin orlistat HDL beta- 8,10,12 adiponectin LDL Orlistat 120 mg LDL CRP orlistat rimonabant A D E 2 ( 12.7% ) ( 10.4% ) ( 9.5% ) ( 8.7% ) ( 7.2% ) Rimonabant ( Acomplia® ) ( 6.4% ) Rimonabant cannabinoid receptor 1 rimonabant ( CB1 ) blockage ( RIO-Europe ) 32 rimonabant BMI 30kg/m2 BMI 27kg/m2 35,36 FDA rimonabant 5 mg 20 mg 3.4kg ( p=0.002 ) Exenatide ( Byetta® ) glucagon-like peptide 159 1 ( GLP-1 ) 2005 H3R 55 H3R antago- nist 56 37-39 ghrelin Neuropeptide Y ( NPY ) 40 ghrelin ( receptor NPY Y1 receptor ( NPY Y1R ) antagonist ) ghrelin R- 57 NPY NA ( anti-sense mRNA ) ghrelin Y1R antagonist 41-43 58 ghrelin ghre- PPAR lin fibrate PPAR Ciliary neurotrophic factor ( CNTF ) agonist PPAR agonist 59,60 CNTF CNTF PPAR agonist 61 PPAR agonist TZD CNTF ( re- combinant human variant ) CNTF ( rhvCNTF ) 44 PPAR antagonist Pramlintide ( Symlin® ) amylin PPAR antagonist 2005 62,63 PPAR 1 2 45-48 topiramate zonisamide bupro- 3 adrenergic receptor agonist pion fluoxetine sertraline dia- zoxide aromatase inhibitor 49 L-796568 ( 3 adrenergic D receptor agonist ) 50, 51 3 adrenergic receptor agonist sibu- Melanocortin melanocyte-stimulating hor- tramine orlistat rimonabant mone/adrenocorticotropin4–10 ( MSH/ACTH4–10 ) melanocortin-4 receptor ( MC4-R ) agonist MC4-R 52 53 54 Histamine H3 receptor ( H3R ) 64 160 15.Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, Wakabayashi I. Chronic central infusion of ghrelin increases hy- pothalamic neuropeptide Y and agouti-related protein mRNA levels and body weight in rats. Diabetes 2001; 50: 2438-43. 16.Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908-13. 17.Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 1.Chu NF. Prevalence of obesity in Taiwan. Obesity Rev 2005; 6: 2001; 86: 5992-5. 271-4. 18.Druce MR, Wren AM, Park AJ, et al. Ghrelin increases food in- 2.Tai TY, Chuang LM, Wu HP, Chen CJ. Association of body build take in obese as well as lean subjects. Int J Obes 2005; 29: 1130- with non-insulin-dependent diabetes mellitus and hypertension 6. among Chinese adults: a 4-year follow-up study. Int J Epidemiol 19.Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine pro- 1992; 21: 511-7. duces dose-related weight loss. Obes Res 1999; 7: 189-98. 3.Wei JN, Sung FC, Lin CC, Lin RS, Chiang CC, Chuang LM. 20.Hanotin C, Thomas F, Jones SP, Leutenegger EP, Drouin P. National surveillance for type 2 diabetes mellitus in Taiwanese Efficacy and tolerability of sibutramine in obese patients: a dose- children. JAMA 2003; 290: 1345-50. ranging study. Int J Obes Relat Metab Disord 1998; 22: 32-8. 4.Changa CJ, Lua FH, Yanga YC, et al. Epidemiologic study of 21.Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, type 2 diabetes in Taiwan. Diabetes Res Clin Pr 2000; 50: S49- Leutenegger E. Long-term maintenance of weight loss after a 50. very-low-calorie diet: a randomized blinded trial of the effica- 5.Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular cy and tolerability of sibutramine. Am J Med 1999; 106: 179- disease: pathophysiology, evaluation, and effect of weight loss: 84. an update of the 1997 American Heart Association scientific 22.Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety statement on obesity and heart disease from the obesity com- of sibutramine for weight loss: a systematic review. Arch Intern mittee of the council on nutrition, physical activity, and Med 2004; 164: 994-1003. metabolism. Circulation 2006; 113: 898-918. 23.Wadden TA, Berkowitz RI, Womble LG, et al. Randomized tri- 6. 91 al of lifestyle modification and pharmacotherapy for obesity. N 4 2002 ( http://www.doh.gov.tw ) Engl J Med 2005; 353: 2111-20. 7.Huda MSB, Wilding JPH, Pinkney JH. Gut peptides and the 24.Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. regulation of appetite. Obesity Rev 2006; 7: 163-82. Sibutramine is effective for weight loss and diabetic control in 8.Marzo VD, Bifulco M, Petrocellis LD. The endocannabinoid obesity with type 2 diabetes: a randomised, double-blind, place- system and its therapeutic exploitation. Nat Rev Drug Discov bo-controlled study. Diabetes Obes Metab 2000; 2: 105-12. 2004; 3: 771-84. 25.McNeely W, Goa KL. Sibutramine: a review of its contribution 9.George K, Sandor B. Novel physiologic functions of endo- to the management of obesity. Drugs 1998; 56: 1093-124. cannabinoids as revealed through the use of mutant Mice. 26.Drent ML, Larsson I, William-Olsson T, et al. Orlistat (Ro 18- Neurochem Res 2001; 26: 1015-21. 0647), a lipase inhibitor, in the treatment of human obesity: a 10.Cota D, Marsicano G, Tschop M, et al. The endogenous cannabi- multiple dose study. Int J Obes Relat Metab Disord 1995; 19: noid system affects energy balance via central orexigenic drive 221-6. .. .. and peripheral lipogenesis. J Clin Invest 2003; 112: 423-31. 27.Sjostrom L, Rissanen A, Andersen T, et al. Randomised place- 11.Steven BH, Andrew SG, Ken F, et al. Recombinant leptin for bo-controlled trial of orlistat for weight loss and prevention of weight loss in obese and lean adults: a randomized, controlled, weight regain in obese patients. Lancet 1998; 352: 167-72. dose-escalation trial. JAMA 1999; 282: 1568-75. 28.Rissanen A. Pharmacological intervention: the antiobesity ap- 12.Hukshorn CJ, Westerterp-Plantenga MS, Saris WH. Pegylated proach. Eur J Clin Invest 1998; 28: 27-30. human recombinant leptin (PEG-OB) causes additional weight 29.Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the loss in severely energy-restricted, overweight men. Am J Clin treatment of obese patients with type 2 diabetes. A 1-year ran- Nutr 2003; 77: 771-6. domized double-blind study. Diabetes Care 1998; 21: 1288-94. 13.Licinio J, Caglayan S, Ozata M, et al. Phenotypic effects of lep- 30.Jarl ST, Jonathan H, Mark NB, Lars S. XENical in the Prevention tin replacement on morbid obesity, diabetes mellitus, hypogo- of Diabetes in Obese Subjects (XENDOS) Study: A random- nadism, and behavior in leptin-deficient adults. Proc Natl Acad ized study of orlistat as an adjunct to lifestyle changes for the Sci 2004; 101: 4531-6. prevention of type 2 diabetes in obese patients. Diabetes Care 14.Considine RV, Sinha MK, Heiman ML, et al. Serum im- 2004; 27: 155-61. munoreactive-leptin concentrations in normal-weight and obese 31.Michael HD, Jonathan H, Mario D, et al.
Load more

Recommended publications
  • Lifestyle Drugs” for Men and Women
    Development of “Lifestyle Drugs” for Men and Women Armin Schultz CRS - Clinical Research Services Mannheim GmbH AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle drugs Smart drugs, Quality-of-life drugs, Vanity drugs etc. Lifestyle? Lifestyle-Drugs? Active development? Discovery by chance? AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle A lifestyle is a characteristic bundle of behaviors that makes sense to both others and oneself in a given time and place, including social relations, consumption, entertainment, and dress. The behaviors and practices within lifestyles are a mixture of habits, conventional ways of doing things, and reasoned actions „Ein Lebensstil ist [...] der regelmäßig wiederkehrende Gesamtzusammenhang der Verhaltensweisen, Interaktionen, Meinungen, Wissensbestände und bewertenden Einstellungen eines Menschen“ (Hradil 2005: 46) Different definitions in social sciences, philosophy, psychology or medicine AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle Many “subdivisions” LOHAS: “Lifestyles of Health and Sustainability“ LOVOS: “Lifestyles of Voluntary Simplicity“ SLOHAS: “Slow Lifestyles of Happiness and Sustainability” PARKOS: “Partizipative Konsumenten“ ……. ……. ……. AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle drugs Lifestyle drug is an imprecise term commonly applied to medications which treat non-life threatening and non-painful conditions such as baldness, impotence, wrinkles, or acne, without any medical relevance at all or only minor medical relevance relative to others. Desire for increase of personal well-being and quality of life It is sometimes intended as a pejorative, bearing the implication that the scarce medical research resources allocated to develop such drugs were spent frivolously when they could have been better spent researching cures for more serious medical conditions.
    [Show full text]
  • Carboxylesterases: Pharmacological Inhibition Regulated Expression and Transcriptional Involvement of Nuclear Receptors and Other Transcription Factors
    CARBOXYLESTERASES: PHARMACOLOGICAL INHIBITION REGULATED EXPRESSION AND TRANSCRIPTIONAL INVOLVEMENT OF NUCLEAR RECEPTORS AND OTHER TRANSCRIPTION FACTORS Yuanjun Shen1, Zhanquan Shi2 and Bingfang Yan2,3 Division of Pharmaceutical Sciences James L. Winkle College of Pharmacy University of Cincinnati Cincinnati, OH 45229 USA. Address Correspondence to: Dr. Bingfang Yan Division of Pharmaceutical Sciences James L. Winkle College of Pharmacy University of Cincinnati Cincinnati, OH 45229 Phone: (513) 558-6297 Fax: (513) 558-3233 E-mail: [email protected] Running Title: Regulated expression and inhibited activity of carboxylesterases FOOTNOTES 1 Current address: Pittsburgh Heart, Lung and Blood Vascular Medicine Institute, University of Pittsburgh Department of Medicine, Pittsburgh, PA 15261, USA. 2 Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45229, USA 3 To whom correspondence should be addressed. 4 This work was supported by National Institutes of Health Grants R01GM61988 and R01EB018748. 5 Abbreviation used: CAR, Constitutive androstane receptor; CES1, carboxylesterase-1; DEC1, Differentiated embryo chondrocyte-1; 5-FU: Fluorouracil; GR, Glucocorticoid receptor; IL-6, Interlekin- 6; LPS, Lipopolysaccharides; Nrf2, Nuclear factor (erythroid-derived 2)-like 2; p53, Tumor protein p53; PXR, Pregnane X receptor Carboxylesterases (CESs, E.C.3.1.1.1) constitute a large class of enzymes that determine the therapeutic efficacy and toxicity of ester/amide drugs. Without exceptions, all mammalian species studied express multiple forms of carboxylesterases. Two human carboxylesterases, CES1 and CES2, are major contributors to hydrolytic biotransformation. Recent studies have identified therapeutic agents that potently inhibit carboxylesterases-based catalysis. Some of them are reversible whereas others irreversible. The adrenergic antagonist carvedilol, for example, reversibly inhibits CES2 but this carboxylesterase is irreversibly inhibited by orlistat, a popular anti-obesity medicine.
    [Show full text]
  • Cyproterone Acetate in the Management of Polycystic Ovary Syndrome
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Journal of Rawalpindi Medical College Journal of Rawalpindi Medical College (JRMC); 2018;22(3): 262-265 Original Article Comparison of Metformin and Ethinyl Estradiol- Cyproterone Acetate in the Management of Polycystic Ovary Syndrome Sadaf Ajaib, Maimoona Ali Department of Gyanecology and Obstetrics, Military Hospital, Rawalpindi Abstract predisposition. The rudimentary quandary is in the hypothalamic pituitary axis leading to incremented Background: To compare ethinyl estradiol- LH/FSH ratio1. The cumulation of anovulation and cyproterone acetate and metformin for polycystic hyperandrogenism denotes the classic form of PCOS ovarian syndrome in terms of mean hirsutism score which exhibits the adverse metabolic phenotype of the and waist hip ratio (WHR). syndrome. Clinical and biochemical features of these Methods: A total of 120 patients (60 patients in patients may vary well-according to race, ethnicity and each group) were included in the study. Group-A the diagnostic criteria used. 2 Hyper-androgenism received metformin 500mg and group-B was given may result in acne and hirsutism. Hirsutism afflicts 5- ethinyl estradiol 35 mg as treatment of polycystic 15% of females and is a paramount denouement of ovary disease (PCOD), mean hirsuitism and waist to background hyper-androgenemia. The manifestations hip ratio was measured at 6months. Hirsuitism was of polycystic ovary syndrome depends largely on measured according to Ferriman Gallway score. obesity, which exacerbates the reproductive and Circumferences were measured with an metabolic aberrations in women tormented by PCOs. anthropometric tape over light clothing. Waist girth Further studies conclude that obesity might promote was measured at the minimum circumference the phenotypic expression of PCOS in a population at between the iliac crest and the rib cage and hip girth risk of this disease.1,2 at the maximum width and their ratio was calculated Well known risk determinants for cardiovascular as baseline and after 6 months of treatment.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0022039 A1 Schwink Et Al
    US 20120022039A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0022039 A1 Schwink et al. (43) Pub. Date: Jan. 26, 2012 (54) NOVEL SUBSTITUTED INDANES, METHOD Publication Classification FOR THE PRODUCTION THEREOF, AND USE (51) Int. Cl. THEREOF AS DRUGS A 6LX 3L/397 (2006.01) C07D 207/06 (2006.01) C07D 2L/22 (2006.01) C07D 22.3/04 (2006.01) (75) Inventors: Lothar Schwink, Frankfurt am C07D 22L/22 (2006.01) Main (DE); Siegfried Stengelin, C07C 235/54 (2006.01) Frankfurt am Main (DE); Matthias C07D 307/14 (2006.01) Gossel, Frankfurt am Main (DE); A63L/35 (2006.01) Klaus Wirth, Frankfurt am Main A6II 3/40 (2006.01) (DE) A6II 3/445 (2006.01) A6II 3/55 (2006.01) A63L/439 (2006.01) A6II 3/66 (2006.01) (73) Assignee: SANOFI, Paris (FR) A6II 3/34 (2006.01) A6IP3/10 (2006.01) A6IP3/04 (2006.01) A6IP3/06 (2006.01) (21) Appl. No.: 13/201410 A6IPL/I6 (2006.01) A6IP3/00 (2006.01) C07D 309/04 (2006.01) (52) U.S. Cl. .................... 514/210.01; 549/426: 548/578; (22) PCT Filed: Feb. 12, 2010 546/205; 540/484; 546/112:564/176; 549/494; 514/459:514/408: 514/319; 514/212.01; 514/299; 514/622:514/471 (86). PCT No.: PCT/EP2010/051796 (57) ABSTRACT The invention relates to substituted indanes and derivatives S371 (c)(1), thereof, to physiologically acceptable salts and physiologi (2), (4) Date: Oct. 4, 2011 cally functional derivatives thereof, to the production thereof, to drugs containing at least one substituted indane according (30) Foreign Application Priority Data to the invention or derivative thereof, and to the use of the Substituted indanes according to the invention and to deriva Feb.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
    US 20150202317A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau et al. (43) Pub. Date: Jul. 23, 2015 (54) DIPEPTDE-BASED PRODRUG LINKERS Publication Classification FOR ALPHATIC AMNE-CONTAINING DRUGS (51) Int. Cl. A647/48 (2006.01) (71) Applicant: Ascendis Pharma A/S, Hellerup (DK) A638/26 (2006.01) A6M5/9 (2006.01) (72) Inventors: Harald Rau, Heidelberg (DE); Torben A 6LX3/553 (2006.01) Le?mann, Neustadt an der Weinstrasse (52) U.S. Cl. (DE) CPC ......... A61K 47/48338 (2013.01); A61 K3I/553 (2013.01); A61 K38/26 (2013.01); A61 K (21) Appl. No.: 14/674,928 47/48215 (2013.01); A61M 5/19 (2013.01) (22) Filed: Mar. 31, 2015 (57) ABSTRACT The present invention relates to a prodrug or a pharmaceuti Related U.S. Application Data cally acceptable salt thereof, comprising a drug linker conju (63) Continuation of application No. 13/574,092, filed on gate D-L, wherein D being a biologically active moiety con Oct. 15, 2012, filed as application No. PCT/EP2011/ taining an aliphatic amine group is conjugated to one or more 050821 on Jan. 21, 2011. polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeu (30) Foreign Application Priority Data tically useful half-lives. The invention also relates to pharma ceutical compositions comprising said prodrugs and their use Jan. 22, 2010 (EP) ................................ 10 151564.1 as medicaments. US 2015/0202317 A1 Jul. 23, 2015 DIPEPTDE-BASED PRODRUG LINKERS 0007 Alternatively, the drugs may be conjugated to a car FOR ALPHATIC AMNE-CONTAINING rier through permanent covalent bonds.
    [Show full text]
  • Clinical Pharmacokinetics and Pharmacodynamics CONCEPTS and APPLICATIONS 18048 FM.Qxd 11/11/09 4:31 PM Page Iii
    18048_FM.qxd 11/11/09 4:31 PM Page i Clinical Pharmacokinetics and Pharmacodynamics CONCEPTS AND APPLICATIONS 18048_FM.qxd 11/11/09 4:31 PM Page iii FOURTH EDITION Clinical Pharmacokinetics and Pharmacodynamics Concepts and Applications Malcolm Rowland, DSc, PhD Thomas N. Tozer, PharmD, PhD Professor Emeritus Professor Emeritus School of Pharmacy and School of Pharmacy and Pharmaceutical Sciences Pharmaceutical Sciences University of Manchester University of California, San Francisco Manchester, United Kingdom Adjunct Professor of Pharmacology Skaggs School of Pharmacy and Pharmaceutical Sciences University of California San Diego With Online Simulations by Hartmut Derendorf, PhD Distinguished Professor Guenther Hochhaus, PhD Associate Professor Department of Pharmaceutics University of Florida Gainesville, Florida 18048_FM.qxd 11/11/09 4:31 PM Page iv Acquisitions Editor: David B. Troy Product Manager: Matt Hauber Marketing Manager: Allison Powell Designer: Doug Smock Compositor: Maryland Composition Inc./ASI Fourth Edition Copyright © 2011 Lippincott Williams & Wilkins, a Wolters Kluwer business 351 West Camden Street 530 Walnut Street Baltimore, MD 21201 Philadelphia, PA 19106 Printed in China All rights reserved. This book is protected by copyright. No part of this book may be reproduced or transmitted in any form or by any means, including as photocopies or scanned-in or other electronic copies, or utilized by any information storage and retrieval system without written permission from the copyright owner, except for brief quotations embodied in critical articles and reviews. Materials appearing in this book prepared by individuals as part of their official duties as U.S. government em- ployees are not covered by the above-mentioned copyright. To request permission, please contact Lippincott Williams & Wilkins at 530 Walnut Street, Philadelphia, PA 19106, via email at permis- [email protected], or via website at lww.com (products and services).
    [Show full text]
  • INN-Nimet 1 1.4.2019 a Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum Abagovomabi Abaloparatide Abaloparatidum Abalopara
    INN-nimet Lääkealan turvallisuus- ja kehittämiskeskus Säkerhets- och utvecklingscentret för läkemedelsområdet Finnish Medicines Agency 1.4.
    [Show full text]
  • Pharmacotherapies for Obesity: Past, Current, and Future Therapies
    Hindawi Publishing Corporation Journal of Obesity Volume 2011, Article ID 179674, 18 pages doi:10.1155/2011/179674 Review Article Pharmacotherapies for Obesity: Past, Current, and Future Therapies Lisa L. Ioannides-Demos, Loretta Piccenna, and John J. McNeil Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Alfred Centre, Commercial Road, Melbourne, VIC 3004, Australia Correspondence should be addressed to Lisa L. Ioannides-Demos, [email protected] Received 4 August 2010; Accepted 24 September 2010 Academic Editor: A. Halpern Copyright © 2011 Lisa L. Ioannides-Demos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Past therapies for the treatment of obesity have typically involved pharmacological agents usually in combination with a calorie- controlled diet. This paper reviews the efficacy and safety of pharmacotherapies for obesity focusing on drugs approved for long- term therapy (orlistat), drugs approved for short-term use (amfepramone [diethylpropion], phentermine), recently withdrawn therapies (rimonabant, sibutamine) and drugs evaluated in Phase III studies (taranabant, pramlintide, lorcaserin and tesofensine and combination therapies of topiramate plus phentermine, bupropion plus naltrexone, and bupropion plus zonisamide). No current pharmacotherapy possesses the efficacy needed to produce substantial weight loss in morbidly obese patients. Meta- analyses support a significant though modest loss in bodyweight with a mean weight difference of 4.7 kg (95% CI 4.1 to 5.3 kg) for rimonabant, 4.2 kg (95% CI 3.6 to 4.8 kg) for sibutramine and 2.9 kg (95% CI 2.5 to 3.2 kg) for orlistat compared to placebo at ≥12 months.
    [Show full text]
  • Fewer Opportunties for Companies to Get Fat Off Obesity Products
    October 24, 2008 Fewer opportunties for companies to get fat off obesity products Lisa Urquhart European regulators yesterday seemingly gave with one hand and then took away with the other in the world of weight loss. An announcement that the watchdog had decided to rescind marketing approval for Sanofi- Aventis' drug Acomplia following reports of adverse psychological effects was released almost at the same time as one giving the go-ahead for over-the-counter sales of GlaxoSmithKline’s alli. The decision by the regulator to suspend sales of Acomplia in all European Union states caused shares in Sanofi-Aventis to fall 6% today to €42.97. It almost certainly spells the end for the anti-obesity treatment that failed to launch in the US following an advisory committee unanimously recommending against its approval, because of concerns over psychiatric effects. Some analysts have now completely removed the drug from their models, but the psychiatric problems that have stalked the drug had already seen many analysts heavily downgrade their sales expectations. According to historic forecasts from EvaluatePharma, 2012 sales consensus has fallen by $499m in the last 12 months to $522m, and are a long cry from the $3.9bn predicted in January 2007. Even in Europe, where the drug was approved in 27 countries, there had been reluctance to prescribe it due to those concerns. Germany turned it down for insurance cover twice this year and France placed restrictive prescription criteria on the drug and only offered to reimburse at a third of the price. The decision by the regulator could also hammer the final nail into the coffin of the cannaboid type 1 antagonist drugs for weight loss, coming only weeks after the decision by Merck & Co to abandon development of taranabant, due to psychological issues.
    [Show full text]
  • Xenical, INN-Orlistat
    SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion for the approval of Xenical. This scientific discussion has been updated until 1 November 2003. For information on changes after this date please refer to module 8B. 1. Introduction Obesity is a disease characterised by an excess body fat. It is often measured by calculation of the body mass index (BMI), i.e. the body weight in kg divided by body surface area in m2. Individuals may be regarded as obese with a BMI >25-27 kg/m² (depending on age). A number of concomitant pathological processes and diseases are associated with obesity including coronary heart disease, hypertension, stroke, non-insulin dependent diabetes mellitus and certain forms of cancer. Besides changes in diet, behaviour and physical activities, obesity may be treated by surgery or pharmacological therapy. All currently available medicinal products for obesity treatment are appetite suppressants (amphetamine-like products) that act via the central nervous system (CNS). However, they may not be prescribed during longer periods than 3 months, due to the potential risk of abuse. Thus, there is a need for medicinal products that can be used in chronic treatment together with dietary and behavioural modifications. Orlistat belongs to a new class of pharmacological agents. It inhibits the action of gastrointestinal lipases and thereby impairs the metabolism of lipids in the intestinal lumen leading to a prevention of lipid absorption. Xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) greater or equal to 30 kg/m², or overweight patients (BMI > 28 kg/m²) with associated risk factors.
    [Show full text]
  • XENICAL, INN-Orlistat
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Xenical 120 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each hard capsule contains 120 mg orlistat. For a full list of excipients, see 6.1. 3. PHARMACEUTICAL FORM Hard capsule. The capsule has a turquoise cap and turquoise body bearing the imprint of “XENICAL 120”. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) greater or equal to 30 kg/m², or overweight patients (BMI > 28 kg/m²) with associated risk factors. Treatment with orlistat should be discontinued after 12 weeks if patients have been unable to lose at least 5 % of the body weight as measured at the start of therapy. 4.2 Posology and method of administration Adults The recommended dose of orlistat is one 120 mg capsule taken with water immediately before, during or up to one hour after each main meal. If a meal is missed or contains no fat, the dose of orlistat should be omitted. The patient should be on a nutritionally balanced, mildly hypocaloric diet that contains approximately 30 % of calories from fat. It is recommended that the diet should be rich in fruit and vegetables. The daily intake of fat, carbohydrate and protein should be distributed over three main meals. Doses of orlistat above 120 mg three times daily have not been shown to provide additional benefit. The effect of orlistat results in an increase in faecal fat as early as 24 to 48 hours after dosing.
    [Show full text]
  • Novel CB1 Receptor Antagonist BAR-1 Modifies Pancreatic Islet Function
    Nava-Molina et al. Nutrition and Diabetes (2020) 10:7 https://doi.org/10.1038/s41387-020-0110-0 Nutrition & Diabetes ARTICLE Open Access Novel CB1 receptor antagonist BAR-1 modifies pancreatic islet function and clinical parameters in prediabetic and diabetic mice Lesly Nava-Molina1,ToyokazuUchida-Fuentes1, Héctor Ramos-Tovar1, Martha Fregoso-Padilla1, Marco Aurelio Rodríguez-Monroy1,AnaV.Vega 1, Gabriel Navarrete-Vázquez 2, Erik Andrade-Jorge1, Rafael Villalobos-Molina1, Ricardo Ortiz-Ortega1 and Alonso Vilches-Flores 1 Abstract Backgrouds: Cannabinoid receptor antagonists have been suggested as a novel treatment for obesity and diabetes. We have developed a synthetic cannabinoid receptor antagonist denominated BAR-1. As the function and integrity of a β-cell cellular structure are important keys for diabetes onset, we evaluated the effects of pharmacological administration of BAR-1 on prediabetic and diabetic rodents. Methods: CD-1 mice fed a hypercaloric diet or treated with streptozotocin were treated with 10 mg/kg BAR-1 for 2, 4 or 8 weeks. Body weight, oral glucose tolerance test, HbA1c, triglycerides and insulin in serum were measured. In isolated islets, we evaluated stimulated secretion and mRNA expression, and relative area of islets in fixed pancreases. Docking analysis of BAR-1 was complemented. Results: BAR-1 treatment slowed down weight gain in prediabetic mice. Fasting glucose–insulin relation also 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; decreased in BAR-1-treated mice and glucose-stimulated insulin secretion was increased in isolated islets, without effects in oral test. Diabetic mice treated with BAR-1 showed a reduced glucose and a partial recovery of islet integrity.
    [Show full text]